Patent for Oncoral approved in Japan
Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the patent application for Oncoral has been approved in Japan. The approval in Japan adds to the already obtained patents in the US and a selected number of countries in Europe and China. The patent secures the intellectual property protection rights for Oncoral until year 2035 plus potential patent extension."We are very pleased to also have the patent for Oncoral approved in Japan as the unmet medical needs for gastric cancer treatment in Japan are significant. More than 115,000 Japanese were diagnosed with gastric